NEW YORK – A new startup called Stitch Bio is combining whole-genome sequencing, CRISPR technology, liquid biopsy, and gene therapy to target cancer cells with gene fusions in order to make them druggable. The company believes its approach is both applicable to a wide variety of cancers and highly precise and individualized.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.